# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN
- Date: 2026-08-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Coleman Ashby-Nakagawa, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-week review on buprenorphine, before a Las Vegas engagement. **S**

## History of present illness

Mr. Presley returns three weeks after starting buprenorphine. Withdrawal settled on the first day, and he has taken 16 mg every morning since, with mild cravings in the evenings after rehearsals and no other opioid. He had weekly phone contact and two counseling sessions. He has taken diazepam 10 mg four times daily and no alprazolam. He used CPAP on 82% of nights, for an average of 6.1 hours, and is less sleepy in the afternoons (Epworth 9). His home blood pressure has averaged 128/82 on amlodipine with valsartan, without ankle swelling or dizziness. His bowels open every one to two days, so he has stopped the senna. He is anxious about the three-week Las Vegas engagement starting in twelve days. He had to leave for a rehearsal before giving a urine sample. **S**

| Element | Detail |
|---|---|
| Buprenorphine | 16 mg daily for three weeks; mild evening cravings; no other opioid |
| Diazepam | 40 mg a day; no alprazolam |
| CPAP | 82% of nights, 6.1 hours average; Epworth 9 |
| Home blood pressure | Average 128/82 |
| Bowels | Every one to two days; senna stopped |
| Mood | PHQ-9 6; GAD-7 8 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better |
| Cardiovascular | Negative | No ankle swelling, dizziness or palpitations |
| Gastrointestinal | Negative | Bowels regular; no nausea |
| Psychiatric | Positive | Anxious about the engagement; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**
- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only **S**
- Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time **S**
- Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg) **S**
- Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily **S**
- Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/82 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 108.2 kg; BMI 32.3 kg/m². All vital signs are synthetic.

Potassium: 4.4 mmol/L; Creatinine: 1.04 mg/dL; eGFR (CKD-EPI 2021): 94 mL/min/1.73 m²; PHQ-9: 6; GAD-7: 8. All results are synthetic.

## Change since baseline

- Potassium: 4 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Creatinine: 1 mg/dL at baseline, 1.04 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 98 mL/min/1.73 m² at baseline, 94 mL/min/1.73 m² at this visit **S**
- PHQ-9: 8 at baseline, 6 at this visit **S**
- GAD-7: 9 at baseline, 8 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Calm and alert; blood pressure 128/82, pulse 76; weight 108.2 kg |
| Eyes | Pupils 3 mm, equal and reactive |
| Neurological | No tremor or sedation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder on buprenorphine** (F11.20). Stable on 16 mg with mild cravings and no other opioid use. Safety reviewed: no thoughts of suicide or self-harm; naloxone in the house and the tour bag. **S**
   - Continue 16 mg daily; prescriptions for the engagement sent to one named pharmacy in Las Vegas.
   - Weekly video visits while away.
   - Urine drug test at the next visit.
2. **Benzodiazepine use disorder on diazepam** (F13.20). Stable on 40 mg a day with buprenorphine settled, so the taper begins, at about 10%. **S**
   - Diazepam 36 mg a day (10 mg three times daily with 2 mg three times daily).
   - No further step during the engagement.
3. **Hypertension, stage 2** (I10). Home average 128/82; potassium 4.4 and creatinine 1.04 three weeks after starting valsartan. **S**
   - Continue amlodipine with valsartan.
4. **Obesity, class 1, with prediabetes** (E66.811). Weight 108.2 kg. With buprenorphine stable and his bowels regular, tirzepatide can be started; it treats both obesity and obstructive sleep apnea, and its gastrointestinal effects will be watched with his history of constipation. **S**
   - Tirzepatide 2.5 mg weekly, the first dose today.
   - Earlier main meal and more walking.
5. **Obstructive sleep apnea on CPAP** (G47.33). Good early adherence and less sleepiness. **S**
   - Travel CPAP for the engagement.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, withdrawal symptoms, cravings and other opioid use | Every visit; weekly contact in the first month | Completed today | 16 mg daily; no withdrawal after the first day; mild evening cravings; weekly calls done |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions |
| Laboratory | Urine drug test, including buprenorphine metabolite and fentanyl | At the start of treatment, then about monthly while doses are changing | Deferred | Not collected: he left for a rehearsal before giving a sample. No harm is evident: the monitoring program shows only this clinic's prescriptions and he reports no other use. Corrective action: sample to be collected at the start of the next visit |
| Medication safety | Naloxone on hand and people taught to use it | Every visit | Completed today | At home and in the tour bag |
| Medication safety | Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace | Every two to four weeks during the taper | Completed today | First step today, 40 to 36 mg a day (10%); no withdrawal symptoms |
| Survey | Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; firearms and medicines locked |
| Survey | Mood (PHQ-9) and anxiety (GAD-7) | At baseline, four to six weeks after a change in treatment, then at each review | Completed today | PHQ-9 6 (item 9 scored 0); GAD-7 8 |
| Examination | Office and home blood pressure (target below 130/80) | Every visit | Completed today | Office 128/82; home average 128/82 |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | Two to four weeks after starting, then every six months | Completed today | Potassium 4.4, creatinine 1.04 three weeks after starting valsartan |
| Examination | Weight and BMI | Every visit | Completed today | 108.2 kg, BMI 32.3 |
| Medication safety | Tirzepatide tolerance: nausea, vomiting, constipation, abdominal pain | At each dose step | Completed today | Baseline before the first dose: no nausea; bowels every one to two days |
| Survey | CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative) | Within the first 30 to 90 days, then at each review | Completed today | 82% of nights, 6.1 hours; Epworth 9 |
| Self-management | Bowel frequency, straining and alarm features | Every visit | Completed today | Every one to two days; senna stopped |
| Examination | Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up | Every visit; ophthalmology every three to six months while recently controlled | Completed today | Drops nightly; no eye symptoms; no new drug that affects eye pressure |
| Self-management | Touring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagement | Before each engagement or tour | Completed today | Written plan for the Las Vegas engagement: one pharmacy, weekly video visits, travel CPAP, naloxone, no taper step while away |

## Goal progress

- Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal. Outcome by 2026-08-07: Buprenorphine 16 mg a day since the consultation; no withdrawal after the first day; cravings low. **S**
- One prescriber and one pharmacy for all controlled medicines. In progress; target 2026-09-23. **S**
- Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping. In progress; target 2026-10-28. **S**
- Home blood pressure below 130/80. Outcome by 2026-08-07: Home average 146/94 to 126/80 on amlodipine and valsartan. **S**
- Lose 5% or more of body weight. In progress; target 2026-10-28. **S**
- CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness. In progress; target 2026-10-28. **S**
- A bowel movement at least every two days without straining. Outcome by 2026-08-07: Every one to two days on buprenorphine and polyethylene glycol. **S**

## Medication changes

- Stopped: Senna 8.6 mg oral tablet, two tablets at bedtime **S**
- Stopped: Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable **S**
- Started: Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time **S**
- Started: Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg) **S**
- Started: Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (J Addict Med 2020;14(2S Suppl 1):1-91)
- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (2022), American Gastroenterological Association (Gastroenterology 2022;163(5):1198-1225)
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024), N Engl J Med 2024;391(13):1193-1205
- Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019), American Academy of Sleep Medicine (J Clin Sleep Med 2019;15(2):335-343)
- CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Preventive visit next week. Weekly video visits during the engagement. Ten-week review after he returns. **S**
- Next scheduled visit 2026-08-14: periodic adult preventive visit. **S**
